Institution identification

PURI

https://redirect.ema.europa.eu/resource/49958

Institution ID

49958

Institution full name and acronym

IQVIA NL, Real-World-Evidence

Institution countries

Netherlands

Type of institution

Other

Institution website

ENCePP partner

Yes
Institution description
IQVIA is a global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry dedicated to creating connections that deliver innovations and actionable insights. As part of IQVIA, IQVIA-NL is specialized in the provision of RWE studies, pharmacoepidemiology and health outcomes. Our consultants develop methods for RWE study designs and execution combining secondary and primary data directly from patients and physicians.
Next to the RWE studies, IQVIA-NL is also specialized in methodological work as development of data quality frameworks and development of specific metadata fields and the population of metadata.
Institution details
Experience with collecting data directly from individual patients or respondents:
Yes
Interest in carrying out research that is funded by pharmaceutical companies:
Yes

Contact

Studies conducted by the institution

DARWIN EU® - Co-prescribing of endothelin receptor antagonists (ERAs) and phosphodiesterate-5 inhibitors (PDE-5is) in pulmonary arterial hypertension (PAH)
DARWIN EU® - Drug utilisation study on medicinal use of cannabis flos
DARWIN EU® - Drug utilisation study on medicinal use of Pelargonii radix
DARWIN EU® Drug utilisation of valproate-containing medicinal products in women of childbearing potential
DARWIN EU® DUS of Antibiotics in the ‘Watch’ category of the WHO AWaRe classification of antibiotics for evaluation and monitoring of use
DARWIN EU® Monitoring prescription of medicines for public health emergencies at risk of shortages
DARWIN EU® Multiple myeloma: patient characterisation, treatments and survival in the period 2012-2022
DARWIN EU® Natural history of dermatomyositis (DM) and polymyositis (PM) in adults and paediatric populations
DARWIN EU® Overall survival in patients with locally advanced or metastatic non-small cell lung cancer treated with selected immunotherapies as first line of treatment
DARWIN EU® Prevalence of rare blood cancers in Europe
DARWIN EU® Treatment patterns of drugs used in adult and paediatric population with systemic lupus erythematosus
DARWIN EU® Use of take-home naloxone for opioid overdose treatment
DARWIN EU® – Frailty and polypharmacy among adults with selected cancers at the time of diagnosis
Establish an EU catalogue of sources of real-world data, characterised by a common set of metadata and data quality measurements
Establish an EU catalogue with metadata of data sources and studies
Study of exposure and use patterns of alternatives to ranitidine-containing medicines in patients treated with ranitidine (Ranitidine)
Study of impact of EU label changes for fluoroquinolone containing medicinal products for systemic and inhalation use - post-referral prescribing trends
Systemic glucocorticoids in the treatment of COVID-19 and risks of adverse outcomes in COVID-19 patients in the primary and secondary care setting (Corticosteroids in COVID19)
Trade-offs between benefits and harms of drugs: a stated preference study with adult patients with cancer in Europe (Patient preferences)